<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p198" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_198{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_198{left:306px;bottom:30px;}
#t3_198{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_198{left:346px;bottom:30px;}
#t5_198{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_198{left:517px;bottom:30px;}
#t7_198{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_198{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_198{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_198{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_198{left:35px;bottom:777px;letter-spacing:0.05px;word-spacing:0.14px;}
#tc_198{left:35px;bottom:754px;letter-spacing:-0.02px;word-spacing:0.21px;}
#td_198{left:35px;bottom:731px;letter-spacing:0.04px;word-spacing:-0.93px;}
#te_198{left:35px;bottom:707px;letter-spacing:0.06px;word-spacing:0.13px;}
#tf_198{left:35px;bottom:684px;letter-spacing:0.1px;word-spacing:-0.53px;}
#tg_198{left:35px;bottom:661px;letter-spacing:0.11px;word-spacing:0.08px;}
#th_198{left:35px;bottom:638px;letter-spacing:0.02px;word-spacing:-0.52px;}
#ti_198{left:35px;bottom:600px;letter-spacing:-0.1px;word-spacing:0.54px;}
#tj_198{left:35px;bottom:575px;letter-spacing:0.11px;word-spacing:-0.74px;}
#tk_198{left:35px;bottom:552px;letter-spacing:-0.02px;word-spacing:0.21px;}
#tl_198{left:35px;bottom:529px;letter-spacing:0.1px;word-spacing:0.09px;}
#tm_198{left:321px;bottom:529px;letter-spacing:-0.03px;word-spacing:0.23px;}
#tn_198{left:494px;bottom:529px;letter-spacing:0.06px;word-spacing:0.13px;}
#to_198{left:35px;bottom:507px;letter-spacing:-0.03px;word-spacing:0.22px;}
#tp_198{left:136px;bottom:514px;letter-spacing:0.06px;}
#tq_198{left:203px;bottom:507px;letter-spacing:0.14px;word-spacing:0.04px;}
#tr_198{left:35px;bottom:484px;letter-spacing:0.06px;word-spacing:0.23px;}
#ts_198{left:35px;bottom:460px;letter-spacing:0.14px;word-spacing:0.05px;}
#tt_198{left:35px;bottom:437px;}
#tu_198{left:42px;bottom:437px;letter-spacing:-0.02px;}
#tv_198{left:35px;bottom:414px;letter-spacing:-0.08px;}
#tw_198{left:35px;bottom:391px;letter-spacing:0.09px;}
#tx_198{left:160px;bottom:391px;letter-spacing:0.43px;}
#ty_198{left:35px;bottom:350px;letter-spacing:0.04px;word-spacing:0.14px;}
#tz_198{left:35px;bottom:327px;letter-spacing:0.1px;word-spacing:0.09px;}
#t10_198{left:418px;bottom:335px;}
#t11_198{left:463px;bottom:327px;letter-spacing:0.43px;word-spacing:-0.24px;}
#t12_198{left:35px;bottom:304px;letter-spacing:0.03px;word-spacing:0.16px;}
#t13_198{left:35px;bottom:281px;letter-spacing:0.12px;word-spacing:0.07px;}
#t14_198{left:35px;bottom:258px;letter-spacing:0.23px;}
#t15_198{left:117px;bottom:265px;letter-spacing:0.06px;}
#t16_198{left:35px;bottom:217px;letter-spacing:0.08px;word-spacing:0.1px;}
#t17_198{left:461px;bottom:217px;letter-spacing:0.17px;}
#t18_198{left:512px;bottom:217px;letter-spacing:0.31px;}
#t19_198{left:35px;bottom:194px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1a_198{left:35px;bottom:171px;letter-spacing:0.13px;word-spacing:-0.62px;}
#t1b_198{left:35px;bottom:148px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1c_198{left:196px;bottom:155px;letter-spacing:0.1px;}
#t1d_198{left:241px;bottom:148px;letter-spacing:-0.01px;word-spacing:0.19px;}
#t1e_198{left:35px;bottom:124px;letter-spacing:0.06px;word-spacing:-0.7px;}
#t1f_198{left:329px;bottom:124px;letter-spacing:0.17px;}
#t1g_198{left:379px;bottom:124px;letter-spacing:0.2px;word-spacing:-0.63px;}
#t1h_198{left:35px;bottom:101px;letter-spacing:-0.01px;word-spacing:-0.63px;}
#t1i_198{left:35px;bottom:78px;letter-spacing:0.21px;word-spacing:-0.76px;}
#t1j_198{left:35px;bottom:55px;letter-spacing:0.17px;}
#t1k_198{left:101px;bottom:62px;letter-spacing:-0.01px;}
#t1l_198{left:123px;bottom:55px;letter-spacing:0.02px;word-spacing:-1.07px;}
#t1m_198{left:618px;bottom:777px;letter-spacing:0.03px;word-spacing:0.15px;}
#t1n_198{left:719px;bottom:777px;letter-spacing:0.17px;}
#t1o_198{left:770px;bottom:777px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1p_198{left:618px;bottom:754px;letter-spacing:0.07px;}
#t1q_198{left:722px;bottom:754px;letter-spacing:0.17px;}
#t1r_198{left:774px;bottom:754px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1s_198{left:618px;bottom:731px;letter-spacing:0.24px;word-spacing:-0.05px;}
#t1t_198{left:821px;bottom:731px;letter-spacing:0.17px;}
#t1u_198{left:873px;bottom:731px;letter-spacing:0.1px;word-spacing:0.08px;}
#t1v_198{left:618px;bottom:707px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t1w_198{left:618px;bottom:667px;letter-spacing:0.02px;word-spacing:0.16px;}
#t1x_198{left:618px;bottom:645px;letter-spacing:0.09px;}
#t1y_198{left:676px;bottom:653px;letter-spacing:0.12px;}
#t1z_198{left:743px;bottom:645px;letter-spacing:0.07px;word-spacing:0.12px;}
#t20_198{left:618px;bottom:622px;letter-spacing:0.05px;word-spacing:0.14px;}
#t21_198{left:978px;bottom:629px;letter-spacing:0.1px;}
#t22_198{left:1023px;bottom:622px;letter-spacing:-0.12px;word-spacing:0.3px;}
#t23_198{left:618px;bottom:599px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t24_198{left:618px;bottom:575px;letter-spacing:0.01px;word-spacing:0.17px;}
#t25_198{left:618px;bottom:552px;letter-spacing:0.05px;}
#t26_198{left:683px;bottom:560px;letter-spacing:0.1px;}
#t27_198{left:728px;bottom:552px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t28_198{left:618px;bottom:529px;letter-spacing:0.08px;word-spacing:0.11px;}
#t29_198{left:618px;bottom:506px;letter-spacing:0.07px;word-spacing:-0.71px;}
#t2a_198{left:618px;bottom:482px;letter-spacing:0.09px;word-spacing:0.09px;}
#t2b_198{left:618px;bottom:459px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2c_198{left:618px;bottom:436px;letter-spacing:-0.01px;word-spacing:0.2px;}
#t2d_198{left:618px;bottom:413px;letter-spacing:0.16px;word-spacing:0.04px;}
#t2e_198{left:809px;bottom:420px;letter-spacing:-0.01px;}
#t2f_198{left:832px;bottom:413px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2g_198{left:618px;bottom:390px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2h_198{left:618px;bottom:366px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2i_198{left:618px;bottom:343px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2j_198{left:618px;bottom:320px;letter-spacing:0.17px;word-spacing:-0.45px;}
#t2k_198{left:618px;bottom:297px;letter-spacing:0.17px;word-spacing:0.02px;}
#t2l_198{left:618px;bottom:273px;letter-spacing:0.14px;word-spacing:-0.87px;}
#t2m_198{left:618px;bottom:250px;letter-spacing:0.14px;word-spacing:0.04px;}
#t2n_198{left:618px;bottom:227px;letter-spacing:0.03px;word-spacing:0.17px;}
#t2o_198{left:618px;bottom:204px;letter-spacing:0.02px;word-spacing:-1.07px;}
#t2p_198{left:618px;bottom:181px;letter-spacing:-0.01px;word-spacing:0.2px;}
#t2q_198{left:618px;bottom:157px;letter-spacing:0.02px;}
#t2r_198{left:661px;bottom:165px;letter-spacing:-0.01px;}
#t2s_198{left:683px;bottom:157px;letter-spacing:0.18px;word-spacing:0.01px;}
#t2t_198{left:618px;bottom:134px;letter-spacing:0.1px;word-spacing:-1.02px;}
#t2u_198{left:618px;bottom:111px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2v_198{left:618px;bottom:88px;letter-spacing:0.01px;word-spacing:-0.65px;}
#t2w_198{left:618px;bottom:64px;letter-spacing:0.02px;word-spacing:-0.33px;}
#t2x_198{left:1099px;bottom:72px;letter-spacing:-0.62px;}
#t2y_198{left:1120px;bottom:64px;letter-spacing:-0.5px;}
#t2z_198{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_198{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_198{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_198{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_198{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_198{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_198{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s6_198{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_198{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s8_198{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s9_198{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts198" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg198Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg198" style="-webkit-user-select: none;"><object width="1210" height="935" data="198/198.svg" type="image/svg+xml" id="pdf198" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_198" class="t s0_198">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_198" class="t s1_198">© </span>
<span id="t3_198" class="t s0_198">(NCCN </span>
<span id="t4_198" class="t s1_198">© </span>
<span id="t5_198" class="t s0_198">), All rights reserved. NCCN Guidelines </span>
<span id="t6_198" class="t s1_198">® </span>
<span id="t7_198" class="t s0_198">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_198" class="t s2_198">NCCN Guidelines Version 4.2024 </span>
<span id="t9_198" class="t s2_198">Head and Neck Cancers </span>
<span id="ta_198" class="t s3_198">MS-57 </span>
<span id="tb_198" class="t s4_198">tumors that have been resected are limited. Extensive safety data are </span>
<span id="tc_198" class="t s4_198">available and may be extrapolated from the management of SCCHN, with </span>
<span id="td_198" class="t s4_198">some NCCN Member Institutions using platinum-based regimens for these </span>
<span id="te_198" class="t s4_198">patients. With regard to unresectable salivary gland tumors, the NCCN </span>
<span id="tf_198" class="t s4_198">Panel had less consensus about chemoradiation (which is reflected in the </span>
<span id="tg_198" class="t s4_198">category 2B recommendations), because there are few published trials. </span>
<span id="th_198" class="t s4_198">Clinical trials are ongoing in this area (eg, NCT01220583, NCT02776163). </span>
<span id="ti_198" class="t s5_198">Systemic Therapy </span>
<span id="tj_198" class="t s4_198">Targeted systemic therapy is increasingly becoming an option for patients </span>
<span id="tk_198" class="t s4_198">with distantly metastatic salivary gland tumors. NGS and other biomarker </span>
<span id="tl_198" class="t s4_198">tests should be used to evaluate AR, </span><span id="tm_198" class="t s6_198">NTRK, HRAS, PIK3CA</span><span id="tn_198" class="t s4_198">, TMB, and </span>
<span id="to_198" class="t s4_198">HER2 status. </span>
<span id="tp_198" class="t s7_198">558,703-712 </span>
<span id="tq_198" class="t s4_198">Since HER2-testing guidelines are currently not </span>
<span id="tr_198" class="t s4_198">available for patients with salivary gland cancers, the panel refers to the </span>
<span id="ts_198" class="t s4_198">ASCO/CAP guidelines for HER2-testing of breast cancers </span>
<span id="tt_198" class="t s4_198">(</span><span id="tu_198" class="t s8_198">https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap- </span>
<span id="tv_198" class="t s8_198">guidelines/recommendations-for-human-epidermal-growth-factor-2-testing- </span>
<span id="tw_198" class="t s8_198">in-breast-cancer</span><span id="tx_198" class="t s4_198">). </span>
<span id="ty_198" class="t s4_198">A significant number of advanced salivary gland tumors with distant </span>
<span id="tz_198" class="t s4_198">metastases are androgen receptor-positive (AR+). </span>
<span id="t10_198" class="t s7_198">705-709 </span>
<span id="t11_198" class="t s4_198">Therefore, the </span>
<span id="t12_198" class="t s4_198">panel recommends that patients with tumors that are AR+ receive </span>
<span id="t13_198" class="t s4_198">androgen receptor therapy (ie, leuprolide, bicalutamide, abiraterone, </span>
<span id="t14_198" class="t s4_198">goserelin). </span>
<span id="t15_198" class="t s7_198">709,713-716 </span>
<span id="t16_198" class="t s4_198">Two phase I/II studies including patients with advanced </span><span id="t17_198" class="t s6_198">NTRK </span><span id="t18_198" class="t s4_198">gene </span>
<span id="t19_198" class="t s4_198">fusion-positive cancer (with 22%–38% being salivary gland tumors) </span>
<span id="t1a_198" class="t s4_198">showed promising objective response rates of 75% to 100% with the TRK </span>
<span id="t1b_198" class="t s4_198">inhibitor larotrectinib. </span>
<span id="t1c_198" class="t s7_198">710,711 </span>
<span id="t1d_198" class="t s4_198">A pooled analysis from a phase II trial and two </span>
<span id="t1e_198" class="t s4_198">phase I trials including 54 patients with </span><span id="t1f_198" class="t s6_198">NTRK </span><span id="t1g_198" class="t s4_198">gene fusion-positive cancer </span>
<span id="t1h_198" class="t s4_198">(13% being mammary analogue secretory carcinoma of the salivary gland) </span>
<span id="t1i_198" class="t s4_198">showed an objective response rate of 57.4% for entrectinib, another TRK </span>
<span id="t1j_198" class="t s4_198">inhibitor. </span>
<span id="t1k_198" class="t s7_198">712 </span>
<span id="t1l_198" class="t s4_198">The FDA approved larotrectinib and entrectinib for treatment of </span>
<span id="t1m_198" class="t s4_198">patients with </span><span id="t1n_198" class="t s6_198">NTRK </span><span id="t1o_198" class="t s4_198">gene fusion-positive tumors, and the panel also </span>
<span id="t1p_198" class="t s4_198">recommends </span><span id="t1q_198" class="t s6_198">NTRK </span><span id="t1r_198" class="t s4_198">therapy options such as larotrectinib and entrectinib </span>
<span id="t1s_198" class="t s4_198">for patients with recurrent </span><span id="t1t_198" class="t s6_198">NTRK </span><span id="t1u_198" class="t s4_198">gene fusion-positive salivary gland </span>
<span id="t1v_198" class="t s4_198">tumors and distant metastases. </span>
<span id="t1w_198" class="t s4_198">HER2 positivity has also been found in some advanced salivary gland </span>
<span id="t1x_198" class="t s4_198">tumors. </span>
<span id="t1y_198" class="t s7_198">707,709,717 </span>
<span id="t1z_198" class="t s4_198">It is recommended that these patients receive a HER2- </span>
<span id="t20_198" class="t s4_198">targeted treatment option such as trastuzumab. </span>
<span id="t21_198" class="t s7_198">709,718 </span>
<span id="t22_198" class="t s4_198">Small series </span>
<span id="t23_198" class="t s4_198">demonstrate that ado-trastuzumab emtansine may be active in patients </span>
<span id="t24_198" class="t s4_198">with previously treated metastatic HER2-positive salivary gland </span>
<span id="t25_198" class="t s4_198">cancers. </span>
<span id="t26_198" class="t s7_198">719,720 </span>
<span id="t27_198" class="t s4_198">Nonrandomized phase II trials have also examined </span>
<span id="t28_198" class="t s4_198">trastuzumab combined with other agents for patients with advanced </span>
<span id="t29_198" class="t s4_198">HER2-positive salivary gland cancers. For example, results from an open- </span>
<span id="t2a_198" class="t s4_198">label, single-center, phase II Japanese study including 57 patients with </span>
<span id="t2b_198" class="t s4_198">recurrent or metastatic HER2-positive salivary gland cancer showed that </span>
<span id="t2c_198" class="t s4_198">trastuzumab combined with docetaxel was associated with a 70.2% ORR </span>
<span id="t2d_198" class="t s4_198">(95% CI, 56.6%–81.6%). </span>
<span id="t2e_198" class="t s7_198">721 </span>
<span id="t2f_198" class="t s4_198">Complete response was reached in 14% of </span>
<span id="t2g_198" class="t s4_198">patients, partial response was reached in 56.1%, and stable disease was </span>
<span id="t2h_198" class="t s4_198">observed in 24.6%. The median PFS was 8.9 months (95% CI, 7.8–9.9), </span>
<span id="t2i_198" class="t s4_198">and OS was 39.7 months (95% CI, not reached). A significant number of </span>
<span id="t2j_198" class="t s4_198">grade 3 or 4 adverse events were reported in this study (89%, with grade </span>
<span id="t2k_198" class="t s4_198">4 adverse events being reported in 61%). The most common serious </span>
<span id="t2l_198" class="t s4_198">adverse events were hematologic: decreased white blood cell, neutrophil, </span>
<span id="t2m_198" class="t s4_198">and lymphocyte counts. Results from the ongoing open-label phase II </span>
<span id="t2n_198" class="t s4_198">MyPathway basket study, including 16 patients with advanced HER2- </span>
<span id="t2o_198" class="t s4_198">positive, -overexpressed, or -amplified salivary gland cancers, showed that </span>
<span id="t2p_198" class="t s4_198">pertuzumab combined with trastuzumab was associated with a 60% </span>
<span id="t2q_198" class="t s4_198">ORR. </span>
<span id="t2r_198" class="t s7_198">722 </span>
<span id="t2s_198" class="t s4_198">Median duration of response for these patients was 9.2 months, </span>
<span id="t2t_198" class="t s4_198">and the regimen was well-tolerated (ie, only one grade 3 treatment-related </span>
<span id="t2u_198" class="t s4_198">adverse event). In a pooled analysis of two studies including 17 patients </span>
<span id="t2v_198" class="t s4_198">with HER2-positive salivary duct carcinoma, fam-trastuzumab deruxtecan- </span>
<span id="t2w_198" class="t s4_198">nxki was associated with an ORR of 47% (all partial responses). </span>
<span id="t2x_198" class="t s7_198">723 </span>
<span id="t2y_198" class="t s4_198">Results </span>
<span id="t2z_198" class="t s9_198">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
